Caplin Point Laboratories: Subsidiary to Acquire Mexican Pharma Company Triwin Pharma Jun 04, 2025
Caplin Point Laboratories' subsidiary, Caplin Point Far East Ltd, has signed an agreement to acquire 100% stake in Triwin Pharma S.A. de C.V., a Mexican pharmaceutical company. This acquisition aims to establish a local presence in Mexico for tender sales, direct sales, marketing, and distribution of Caplin Point's products. The deal is expected to be completed within 30 days, subject to closing conditions and regulatory approvals.
Caplin Point Laboratories: Q4 Profit Up 17%, Declares ₹3 Dividend May 15, 2025
Caplin Point Laboratories' Subsidiary Secures FDA Approval for Haloperidol Decanoate Injection May 14, 2025
Caplin Point's Subsidiary Secures USFDA Approval for Vital Injectable Drug Apr 23, 2025
Caplin Point Laboratories Expands into Chilean Pharmaceutical Market through Strategic Acquisition Apr 03, 2025
More news about Caplin Point Laboratories
02Apr 25
Caplin Point Laboratories Expands Footprint in Chile with Strategic Acquisition
Caplin Point Laboratories' subsidiary, Caplin Point Far East Limited, has acquired Neoethicals Chile SpA, a pharmaceutical marketing and distribution company in Chile. The acquisition, completed on April 1, 2025, involved purchasing 3,000 shares at 1,000 Chilean Pesos per share, totaling approximately USD 3,000. Neoethicals Chile SpA, incorporated in 2015, has shown significant growth with a turnover of 278,565,412 Chilean Pesos (USD 295,222) in 2024. This strategic move aims to establish a direct sales and distribution channel in Chile, strengthening Caplin Point's position in the South American pharmaceutical market.
27Feb 25
Caplin Steriles Secures FDA Approval for Glaucoma Treatment, Tapping into $242 Million Market
Caplin Steriles, a subsidiary of Caplin Point Laboratories, has received USFDA approval for its ANDA for Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution. The approved eye drops, equivalent to COMBIGAN, are indicated for reducing elevated intraocular pressure in glaucoma or ocular hypertension patients. The product had US sales of approximately $242 million for the 12-month period ending December 2022. Caplin Steriles has developed 46 ANDAs, secured 34 approvals, and plans to expand its portfolio with over 40 products in the next four years.